核糖核苷酸还原酶M2与恶性肿瘤的研究进展  

Research Progress of Ribonucleotide Reductase M2 and Malignant Tumors

作　　者：艾素芬 黄龙[1] 丁剑午[1] AI Su-fen;HUANG Long;DING Jian-wu(Department of Oncology,The Second Affiliated Hospital of Nanchang Universit;Jiangxi Provincial Key Laboratory of Clinical Transformation of Tumor,Nanchang 330006,China)

机构地区：[1]南昌大学第二附属医院肿瘤科,江西省肿瘤临床转化重点实验室,南昌330006

出　　处：《实用临床医学（江西）》2018年第9期100-103,共4页Practical Clinical Medicine

摘　　要：核糖核苷酸还原酶M2(RRM2)是脱氧核糖核酸(DNA)合成及修复过程中不可缺少的一种关键酶,是核糖核苷酸还原酶(RR)活性的主要调控元件。研究发现RRM2在多种恶性肿瘤中均过表达,本文就RRM2在恶性肿瘤中的表达及RRM2过表达与恶性肿瘤生存预后、增殖、转移、化疗耐药性之间关系的研究进展进行综述,旨在为临床恶性肿瘤的诊断、治疗、预后提供新的理论依据。Ribonucleotide reductase M2 （RRM2）,an indispensable key enzyme in DNA synthesis and repair,is one of the main regulatory elements of ribonucleotide reductase activity.In recent years,RRM2 has been found to be overexpressed in a variety of malignancies.This article reviews the effects of RRM2 overexpression on the prognosis,proliferation,metastasis and chemoresistance of malignant tumors,and provides a new theoretical basis for the diagnosis,treatment and prognosis of malignant tumors.

关 键 词：核糖核苷酸还原酶M2 过表达 恶性肿瘤 预后 增殖 转移 化疗耐药性 

分 类 号：R730.3[医药卫生—肿瘤]